Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

BIA and bioProcessUK Welcome GlaxoSmithKline Manufacturing Investment

Published: Monday, September 24, 2012
Last Updated: Monday, September 24, 2012
Bookmark and Share
GlaxoSmithKline to invest £500 million in manufacturing facilities in the UK.

The BioIndustry Association and bioProcessUK welcomes announcement that GlaxoSmithKline is to invest £500 million in manufacturing facilities in the UK, including £350 million in building a new biopharmaceutical manufacturing facility in Ulverston, Cumbria.

Glyn Edwards, BIA Interim Chief Executive, said: "GlaxoSmithKline's confirmation that it will build a new biopharmaceutical manufacturing facility in the UK is a fantastic boost for the UK's life sciences sector. The investment recognizes that the UK is one of the world's leading locations for life sciences discovery, development and manufacturing and that recent changes to the corporate tax system make the UK an increasingly attractive place for investment. GlaxoSmithKline acknowledged that this investment is on the back of the government's "patent box" legislation, which was first proposed in the BIA-supported Bioscience Innovation and Growth Team's Review and Refresh of Bioscience 2015 report."

Tony, Bradshaw, Co Director of the HealthTech and Medicines Knowledge Transfer Network, said: "The BIA and bioProcessUK believe this is a critically important announcement that will start to capture the value of the UK's competitive biopharmaceutical research capability. The important tax benefits provided by the patent box, and commitment to a decreasing corporation tax, will leverage this world class capability increasing investment, creating jobs and provide the UK with the opportunity to make, as well as discover, the next generation of advanced medicines in the UK."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Biomolecular Manufacturing ‘On-the-Go’
Wyss Institute team unveils a low-cost, portable method to manufacture biomolecules for a wide range of vaccines, other therapies as well as diagnostics.
Molecular Switch Aids Immune Therapy
Researchers identify strategy to maximise effectiveness of immune therapy through molecular switch controlling immune suppression.
Novavax RSV F Vaccine Fails Phase 3 Trial
Novavax announces topline RSV F Vaccine data from two clinical trials in older adults.
GSK’s Shingles Vaccine Candidate Shows High Efficacy
The vaccine candidate showed high efficacy against shingles and its complications in adults aged 70yrs+ in phase III study.
Eisai Establishes AiM Institute
The Andover innovative Medicines (AiM) Institute will develop innovative precision medicines for hard-to-treat conditions.
Antibodies that Target Holes in HIV's Defence Identified
Scientists suggest 'holes' in HIV sugar sheild can be targeted by antibodies.
Discovery Could Yield Improved Flu Vaccines
Researchers have discovered a type of immune antibody that can evolve to combat a number of infuenza virus strains.
First Accurate Simulation of a Virus Invading a Cell
For the first time, scientists know what happens to a virus’ shape when it invades a host cell.Understanding how the virus shape specifically changes could lead to more effective anti-viral therapies.
Developing a Vaccine for Sexually Transmitted and Insect-Borne Zika Infections
Prokarium announce the beginning of a programme to develop an oral vaccine against Zika infection.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!